Levodopa may be one additional risk factor for BMD loss in PD patients. Bone Mineral Density (BMD) is low in Parkinsons Disease (PD) patients in comparison with age-matched healthy individuals. Bone loss in PD, have some reasons such as immobility, decreased muscle strength and low body weight which leads PD patients to experience osteoporotic symptoms. Basically, carbidopa, which is used in PD to prevent conversion of the levodopa to dopamine, prevents 5-Hydroxytryptophan (5- HTP) metabolism in the liver and causes decreased levels of serotonin in the blood. carbidopa by increasing bone formation rate and compensating BMD loss, which is the main aspect of osteoporosis, in PD patients may lead to reduce osteoporotic symptoms. So the carbidopa should be added to the levodopa to reduce the levodopa side effect on BMD loss in PD patients.
The benefits of Open Access journals are apparent enough to raise awareness among scientists and other stakeholders to support for more Open Access Publications from the publishing groups.
Last date updated on January, 2021